Skip to main content

Published locations for Trial data suggest beneficial class effects of SGLT2 inhibitors, including dapagliflozin

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Trial data suggest beneficial class effects of SGLT2 inhibitors, including dapagliflozin

User login

  • Reset your password
  • /content/trial-data-suggest-beneficial-class-effects-sglt2-inhibitors-including-dapagliflozin
  • /familypracticenews/article/170443/diabetes/trial-data-suggest-beneficial-class-effects-sglt2
  • /internalmedicinenews/article/170443/diabetes/trial-data-suggest-beneficial-class-effects-sglt2
  • /vascularspecialistonline/article/170443/diabetes/trial-data-suggest-beneficial-class-effects-sglt2
  • /clinicalendocrinologynews/article/170443/diabetes/trial-data-suggest-beneficial-class-effects-sglt2
  • /diabeteshub/article/170443/diabetes/trial-data-suggest-beneficial-class-effects-sglt2-inhibitors
  • /ecardiologynews/article/170443/diabetes/trial-data-suggest-beneficial-class-effects-sglt2-inhibitors
  • /cardiology/article/170443/diabetes/trial-data-suggest-beneficial-class-effects-sglt2-inhibitors
  • /endocrinology/article/170443/diabetes/trial-data-suggest-beneficial-class-effects-sglt2-inhibitors
  • /internalmedicine/article/170443/diabetes/trial-data-suggest-beneficial-class-effects-sglt2
  • /familymedicine/article/170443/diabetes/trial-data-suggest-beneficial-class-effects-sglt2-inhibitors
  • /type-2-diabetes-icymi/article/170443/diabetes/trial-data-suggest-beneficial-class-effects-sglt2